logo
Share SHARE
FONT-SIZE Plus   Neg

Wave Systems Board Okays 1-for-4 Reverse Split - Quick Facts

Wave Systems Corp. (WAVX) announced that, following shareholder approval at the company's annual meeting on June 20, 2013, the Board of Directors has approved a 1-for-4 reverse split of the company's common stock. The reverse stock split will be in effect at the commencement of trading Monday, July 1, 2013.

The company said that the reverse split is being implemented for purposes of regaining compliance with the $1.00 per share minimum closing bid price requirement for continued listing on the Nasdaq Capital Market.

For every four shares held, Wave shareholders will receive in exchange one new share of Wave Systems common stock. Shareholders otherwise entitled to fractional shares as a result of the reverse stock split will receive cash payments in lieu of those fractional shares, the company said.

The number of common shares issued and outstanding (Class A and Class B combined) will be reduced to approximately 29.2 million from approximately 116.9 million. Shareholders' percentage ownership in the company will remain unchanged as a result of the reverse split, the company noted.

The company believes that the reverse stock split will enable it to regain compliance with the $1 per share minimum closing bid price continued listing requirement.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Sony announced Project Field, a new play way to bring card games to life, along with a host of smartphone games at an event in Japan, aiming to accelerate mobile drive. Project Field is a Japan-only card collection platform where actual physical cards will work with a smartphone app. The first title to be announced is based on Yo-kai Watch for mobile. There is no news about an international releas Shares of Credit Suisse Group AG gained around 8 percent in the morning trading in Zurich after the Swiss banking giant raised its group cost savings target, and also confirmed its medium-term 2018 pre-tax income target. It is almost the end of the year. With the exception of a few, many of the biotech stocks, like the following, on which investors had bet big this year have served up only heartbreak. Now, let's take a look at some of the pending clinical trial catalysts of this month, which will make it a December to remember.
comments powered by Disqus
Follow RTT